STAMFORD, Conn., March 30, 2011 /PRNewswire/ -- Attendees of the 60th annual American College of Cardiology (ACC) Scientific Session in New Orleans, La., can see first hand the benefits of Synapse® 3D from FUJIFILM Medical Systems U.S.A., Inc. Available for sale in the U.S., Synapse 3D is a comprehensive suite of clinical applications that is integrated directly into Synapse® Cardiovascular, Fujifilm's CVIS / C-PACS. During the ACC conference Fujifilm will demonstrate the product's diagnostic benefits and explain how it can enhance workflow and reporting while also providing cost savings.
Developed by Fujifilm and utilizing the company's core competency in image processing, Synapse 3D can enhance clinical capabilities with its broad range of applications such as CT coronary angiography, CT and MR cardiac function analysis, calcium scoring, and cardiac fusion, allowing fusion of PET, MR, CT, SPECT, CT Function or MR Function. Other standard tools included are 2D, 3D (includes stenosis and plaque measurements), and 4D viewer, Sector MPR (multi-planar reconstruction), and Dynamic Data. Using Fujifilm's patented algorithms, Synapse 3D delivers image visualization benefits such as precise segmentation and analysis. Additionally, the application is powered by an enterprise, scalable server-based rendering technology that enables the cardiologist to perform the analysis quickly.
"By combining Fujifilm's core strength in image processing with our ability to integrate our 3D product with our CVIS/C-PACS, we are able to deliver a solution with unrivaled benefits," said Jim Morgan, Fujifilm's Vice President, Medical Informatics. "During trials and research Synapse 3D has proven to be a powerful and efficient diagnostic tool, and we're confident that we will be seeing widespread adoption by cardiologists."
Cardiologists can expect both workflow and reporting improvements from Synapse 3D because of its integration with Synapse Cardiovascular. Unlike similar products that require cardiologists to launch a third party application, Synapse 3D is enterprise capable and is available from within the Synapse Cardiovascular application at any workstation where other Synapse products are in use. This streamlines workflow by avoiding redundant log-ins and the launch of multiple applications, and also minimizes training since users will recognize an intuitive user interface.
Reporting is made easier and more accurate as a result of the product integration, which creates one common user database designed to further optimize workflow and improve patient care. Measurements made in Synapse 3D are directly imported by the Synapse Cardiovascular database and automatically pre-populated into the structured report, giving the referring physician a highly consistent, easy to follow outcome report. And, when coupled with Synapse Cardiovascular's remote reading capabilities, studies can be accessed and interpreted anywhere. Because this solution is able to meet the advanced imaging needs of a cardiology department and eliminates the need for costly, single-use, proprietary workstations, it can be considerably more affordable than other systems.
For more information on Synapse 3D or for a product demonstration, visit FUJIFILM Medical Systems U.S.A. April 3 - 5 at ACC booth # 2001.
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women's health imaging systems, Fujifilm has products that are ideal for any size imaging environment. FUJINON is a subsidiary of FUJIFILM Medical Systems U.S.A., Inc., and supplies technologically advanced endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information visit www.fujimed.com.
© 2011 FUJIFILM Medical Systems U.S.A., Inc.
|SOURCE FUJIFILM Medical Systems USA, Inc.|
Copyright©2010 PR Newswire.
All rights reserved